Attending physician, Inpatient addiction consult service
Faculty member, Addiction medicine fellowship
Faculty member, Addiction psychiatry fellowship
Recognition & Awards
Colorado Health Service Corps, Colorado Department of Public Health & Environment
3-year service commitment to substance use disorder treatment in high need area
5280 Top Doc for Addiction Medicine, 5280 Magazine
My research interests are focused on novel interventions for hospitalized patients with substance use disorders.
Terasaki D. Self-reported Past Experiences With Naltrexone and Attitudes Toward Daily Adherence Among High-utilization Patients With Alcohol Use Disorder. J Addict Med. 2023 Jan 17. [Epub ahead of print] PubMed PMID: 36728042
Terasaki D, Brady J. Severe, Nondelirium Agitation as an Underreported Characteristic of Precipitated Fentanyl Withdrawal: A Case Report. J Addict Med. 2023 Jan-Feb 01;17(1):111-113. PubMed PMID: 35914120
Terasaki D. Cardiovascular medications on discharge for patients with chest pain and concurrent cocaine use. Am J Emerg Med. 2022 Mar 4;. doi: 10.1016/j.ajem.2022.02.060. [Epub ahead of print] PubMed PMID: 35279327.
Terasaki D, Shaffie R, Loh R (2022). Characteristics of hospitalized patients whose substance use increased amid the impacts of COVID-19. The Hospitalist. Online publication. March 3, 2022. Available at: https://www.the-hospitalist.org/
Terasaki D, Loh R, Cornell A, Taub J, Thurstone C. Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates. Addict Sci Clin Pract. 2022 Nov 22;17(1):64. PubMed PMID: 36419181
Terasaki D. Cardiovascular medications on discharge for patients with chest pain and concurrent cocaine use. Am J Emerg Med. 2022 Aug;58:315-316. PubMed PMID: 35279327
Mortaji P, Terasaki D, Moo-Young J. Advanced Inpatient Management of Opioid Use Disorder in a Patient Requiring Serial Surgeries. J Gen Intern Med. 2021 Aug;36(8):2448-2451. PubMed PMID: 33782885
Terasaki D (2021). Methadone disposition on a Friday. SGIM Forum 44 (8): 8, 12.
Terasaki D & Klie K. Tramadol withdrawal in setting of buprenorphine induction, a case report. Journal of Addiction Medicine. May/Jun 2020;14(3):264-266.
Terasaki, D. (2019) Clinical Harm Reduction for Addiction: A Strategy Internists Can (And Do) Embrace. SGIM Forum 42 (9): 5, 9.
Terasaki D, Smith C, Calcaterra SL. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. Pharmacotherapy. 2019 Oct;39(10):1023-1029. PubMed PMID: 31348544